Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 aducanumab in early Alzheimer's disease
NL-OMON47381Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aducanumab in Alzheimer's disease (AD) (3 arms), sponsored by Biogen. Primary endpoint: Change from baseline in CDR-SB score at Week 78. Started Mar 2016; status: active, not recruiting.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON47381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47381.